Table 1.

Approved Asian-origin COVID-19 vaccines and their developers, dose, efficacy, stability, technological platforms, and clinical trials number.

Sl. No.	Name of Vaccines	Developer of the Vaccines	Country of Origin	Dose	Efficacy	Stability (Temperature °C)	Technological Platforms	Clinical Trials No	References
1.	Ad5-nCoV	Beijing Institute of Biotechnology, CanSino Biologics	China	Single dose	66%	2–8	Modified adenovirus vector vaccines	NCT04380701, NCT04523571, NCT04368728, NCT04368728	[45]
2.	BBIBP-CorV (Sinopharm)	China National Pharmaceutical Group Corporation, Beijing Institute of Biological Products, Wuhan Institute of Biological Product	China	Double doses (four to three weeks interval)	79.3%	2–8	Conventional inactivated vaccines	NCT04560881	[46]
3.	Sputnik V (Gamaleya)	Gamaleya Research Institute of Epidemiology and Microbiology	Russia	Double doses (three weeks interval)	91.6%	18	Viral vector vaccines	NCT04436471, NCT04437875, NCT04530396	[47]
4.	ZF2001 (RBD-Dimer)	Chinese Academy of Sciences, Anhui ZhifeiLongcom Biologic Pharmacy Co. Ltd.	China	Triple doses (30 days interval)	72%	-	Protein subunit vaccines	NCT04646590	[48]
5.	CoronaVac	Sinovac Biotech Ltd.	China	Double doses (two weeks interval)	78%	2–8	Conventional inactivated vaccines	NCT04551547, NCT04383574, NCT04352608, NCT04617483, NCT04582344, NCT04508075	[49]
6.	EpiVacCorona	State Research Center of Virology and Biotechnology VECTOR	Russia	Double doses (four weeks interval)	-	2–8	Protein subunit vaccines	NCT04527575, NCT04780035	[50]
7.	BBV152 (Covaxin)	Indian Council of Medical Research (ICMR), and Bharat Biotech Ltd.	India	Double doses (four weeks interval)	81%	2–8	Conventional inactivated vaccines	NCT04641481, NCT04471519	[51]
8.	CoviVac	Russian Academy of Sciences	Russia	Double doses (two weeks interval)	-	2.8	Conventional inactivated vaccines	NCT04619628	[52]